MX2021001804A - Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. - Google Patents

Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.

Info

Publication number
MX2021001804A
MX2021001804A MX2021001804A MX2021001804A MX2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A
Authority
MX
Mexico
Prior art keywords
smarca2
compositions
urea compounds
atpase inhibitors
brm
Prior art date
Application number
MX2021001804A
Other languages
English (en)
Inventor
Troy Douglas Smith
Christopher Adair
Julien Papillon
Katsumasa Nakajima
Rukundo Ntaganda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021001804A publication Critical patent/MX2021001804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporciona un compuesto de Fórmula (I), o una sal farmacéuticamente aceptable del mismo, que ha demostrado ser útil para el tratamiento de una enfermedad o un trastorno mediados por BRM y/o mediados por BRG1: (ver Fórmula) Fórmula (I) en donde R1 a R6 son como se define en la presente descripción.
MX2021001804A 2018-08-17 2019-08-12 Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. MX2021001804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17
PCT/IB2019/056847 WO2020035779A1 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as smarca2/brm atpase inhibitors

Publications (1)

Publication Number Publication Date
MX2021001804A true MX2021001804A (es) 2021-04-19

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001804A MX2021001804A (es) 2018-08-17 2019-08-12 Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.

Country Status (21)

Country Link
US (2) US11958846B2 (es)
EP (2) EP3837256B1 (es)
JP (1) JP7328323B2 (es)
KR (1) KR20210047313A (es)
CN (2) CN112585136B (es)
AU (1) AU2019322325B2 (es)
BR (1) BR112021002632A2 (es)
CA (1) CA3107097A1 (es)
CY (1) CY1126039T1 (es)
DK (1) DK3837256T3 (es)
ES (1) ES2946060T3 (es)
FI (1) FI3837256T3 (es)
HR (1) HRP20230477T1 (es)
HU (1) HUE061963T2 (es)
LT (1) LT3837256T (es)
MX (1) MX2021001804A (es)
PL (1) PL3837256T3 (es)
PT (1) PT3837256T (es)
RS (1) RS64238B1 (es)
SI (1) SI3837256T1 (es)
WO (1) WO2020035779A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112153984A (zh) 2018-01-30 2020-12-29 福宏治疗公司 化合物及其用途
KR20220133258A (ko) 2020-01-29 2022-10-04 포그혼 쎄라퓨틱스 인크. 화합물 및 이의 용도
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
RU2292344C2 (ru) 2001-05-24 2007-01-27 Лео Фарма А/С Производные пиридилцианогуанидинов и фармацевтическая композиция на их основе
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SI2130537T1 (sl) 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
KR20100135255A (ko) 2008-03-14 2010-12-24 오츠카 세이야쿠 가부시키가이샤 Ｍｍｐ-2 및/또는 ｍｍｐ-9 저해제
JP6665154B2 (ja) 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN105481723B (zh) 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2018187414A1 (en) 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Also Published As

Publication number Publication date
ES2946060T3 (es) 2023-07-12
CN112585136A (zh) 2021-03-30
CN112585136B (zh) 2024-06-25
KR20210047313A (ko) 2021-04-29
PT3837256T (pt) 2023-05-23
RS64238B1 (sr) 2023-06-30
EP3837256B1 (en) 2023-03-08
US20210323956A1 (en) 2021-10-21
EP3837256A1 (en) 2021-06-23
US20240270738A1 (en) 2024-08-15
SI3837256T1 (sl) 2023-07-31
LT3837256T (lt) 2023-06-12
FI3837256T3 (fi) 2023-05-15
CY1126039T1 (el) 2023-11-15
HRP20230477T1 (hr) 2023-07-21
US11958846B2 (en) 2024-04-16
CN118666832A (zh) 2024-09-20
AU2019322325B2 (en) 2022-01-20
EP4219488A1 (en) 2023-08-02
CA3107097A1 (en) 2020-02-20
JP2021534147A (ja) 2021-12-09
BR112021002632A2 (pt) 2021-05-11
DK3837256T3 (da) 2023-05-30
PL3837256T3 (pl) 2023-07-10
HUE061963T2 (hu) 2023-09-28
WO2020035779A1 (en) 2020-02-20
AU2019322325A1 (en) 2021-02-18
JP7328323B2 (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
MX2021012105A (es) Compuestos de pirrol.
MX2023006063A (es) Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
MX2020013852A (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2021014458A (es) Compuestos triciclicos.
CR20210148A (es) Compuestos de isoxazol carboxamida y usos de los mismos
MX2023012678A (es) Moduladores de exonucleasa 1 de tres reparaciones principales (trex1).
MX2023015126A (es) Compuestos y metodos para tratar la hiperpotasemia.
WO2020096916A3 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2023002539A (es) Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).